Global Chronic Bacterial Prostatitis Market – Industry Trends and Forecast to 2029

Global Chronic Bacterial Prostatitis Market, By Diagnosis (Urine Test, Blood Test, Post-Prostatic Massage, Imaging Tests, Others), Treatment (AntibioticsLaxative, Analgesic, Others), Route of Administration (Oral, Parenteral, Rectal, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Chronic Bacterial Prostatitis Market Analysis and Size

Chronic Bacterial Prostatitis is a common condition, with 35–50% of men tend to be affected by symptoms indicating prostatitis during their lifetime. Based on a population of >10 600 participants, an 8.2% occurrence of prostatitis symptoms has been found. The four main symptom domains are lower urinary tract symptoms (LUTS – voiding or storage symptoms), urogenital pain, psychological issues and sexual dysfunction. Patients should be managed as per their individual symptom patterns. Several options for first-line treatment includes antibiotics, α-adrenergic antagonists and simple analgesics.

Data Bridge Market Research analyses a growth rate in the global chronic bacterial prostatitis market in the forecast period 2022-2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Chronic Bacterial Prostatitis Market Scope and Segmentation

Market Definition

Chronic bacterial prostatitis is a rare condition in which recurrent infection occurs in the prostate and leads to swelling, inflammation, and frequent urinary tract infections (UTIs). Chronic bacterial prostatitis infection in the prostate can be very painful and includes symptoms such as blood in the pain or burning with urination, urine or semen, foul-smelling urine, sepsis and others.  Chronic prostatitis can present with a huge variety of signs and symptoms. Identification of individual symptom patterns and a symptom-based treatment approach are recommended.  

Global Chronic Bacterial Prostatitis Market Dynamics

Drivers

• Availability of Advanced Treatment Procedures

With each passing decade, varied treatment methods are becoming available that would help the aster recovery of the patients. Chronic bacterial prostatitis is treated with several antibiotics and analgesics. It would help better understand the disease driving the market growth. Thus, it acts as a major driver in the market growth.

• Rising Demand for Probiotics

Probiotics are considered to be a natural and alternative treatment for chronic bacterial prostatitis and are also particularly helpful if one has bacterial prostatitis, especially when the patient is on antibiotics. Probiotics are considered to be beneficial for managing prostatitis, mainly when they are used in combination with supplements as part of phytotherapy. Thus, these analgesics are creating much awareness about the market and is boosting the growth of the market.

Opportunities

• Increase in the number of research and development activities       

The market growth is boosted by the rise in the number of R&D activities. This will provide beneficial opportunities for the global chronic bacterial prostatitis market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives.

• Increasing Demand for Retail Pharmacies

The rise in the number of chronic bacterial prostatitis drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible. The inclusion of numerous medicines under the over-the-counter category and preference for self-medication is anticipated to boost the segment.

 Restraints/Challenges

• Side Effects of Visceral Pain Drugs

The side effects associated with these chronic bacterial prostatitis drugs could curb the growth of the global chronic bacterial prostatitis market over a forecast period. Effects such as racing heartbeat, leg swelling, fatigue, anxiety, fever can hamper the market growth.

• Patent Expiration of Major Drugs

Patent expiration of leading drugs is expected to impede market growth in the near future. Most of the top biologic and pharmaceutical products have lost their patents in the last few years and some are anticipated to go off patent in the near future. For instance, Humira (Adalimumab), a leading biologic brand used for the treatment of intestinal bowel disease from AbbVie, lost its patent in 2016. In addition to this, Johnson & Johnson’s Remicade lost patent in 2014. Recently launched biosimilar and generic treatment products have recorded huge year-on-year growth rate and are expected to capture a major share of the market in the near future.

This global chronic bacterial prostatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic bacterial prostatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Chronic Bacterial Prostatitis Market            

COVID-19 has a major health crisis on the visceral pain market size. In clinical trials, the possibility of chronic bacterial prostatitis has major consequences during the COVID-19 pandemic. When COVID-19 patients witness severe abdominal pain, the chronic bacterial prostatitis should be considered in the primary diagnosis, imaging diagnostics, and laboratory workups. It was a tough job for major players and researchers to perform clinical trials during the pandemic. In contrast, several market players and governments are investing in R&D activities to develop novel drugs for chronic bacterial prostatitis.

Global Chronic Bacterial Prostatitis Market Scope

The global chronic bacterial prostatitis market is segmented on the basis of diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Urine Test
• Blood Test
• Post-Prostatic Massage
• Imaging Tests
• Others

Treatment

• Antibiotics
• Laxative
• Analgesic
• Others

Route of Administration

• Oral
• Parenteral
• Rectal
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Chronic Bacterial Prostatitis Market Regional Analysis/Insights

The global chronic bacterial prostatitis market is analyzed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global chronic bacterial prostatitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing the highest growth for global chronic bacterial prostatitis market throughout the forecast period due to increased government awareness programs and number of generic drugs. 

North America dominates the market due to the presence of key manufacture of the product and increased prevalence of bacterial prostatitis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Chronic Bacterial Prostatitis Market Share Analysis

The global chronic bacterial prostatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global chronic bacterial prostatitis market.

Key players operating in the global chronic bacterial prostatitis market include:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• AbbVie Inc.(Ireland)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Sun Pharmaceutical Industries Ltd (India)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Lupin (India)
• Cipla Inc (India)
• Aurobindo Pharma (India)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)
• Genentech, Inc (U.S.)
• Bausch Health Companies Inc. (Canada)
• Amneal Pharmaceuticals LLC. (U.S.)
• Apotex Inc. (Canada)